Anatara reaches required level for recruitment in trial for IBS treament

Anatara Lifesciences Ltd (ASX:ANR) has enrolled 60 participants for Stage 2 of its key trial to assess candidate GaRP (Gastrointestinal ReProgramming) for the treatment of IBS (irritable bowel syndrome).

Among these 60 are more than 25 high potential participants in the final screening process.

Anatara had intended to complete enrollments by the end of 2024, and with the participant level at the required level for Stage 2, no more recruitment will be occurring beyond December 13 – although the screening process will continue.

Participants have been recruited across four sites across the eastern mainland states of Australia and Adelaide.

The company is expecting headline readouts in the first quarter of 2025.

Anatara’s Executive Chair Dr. David Brookes said the trial recruitment was continuing at a pleasing rate.

“We intend to pause recruitment at the end of next week and will decide about any need for resumption early in the New Year,” he said.

“This only leaves a short window of days for any new participants to be involved in the screening process.

“I really encourage any IBS sufferers considering involvement, and who meet the criteria sub-types of IBS-Diarrhoeal predominant or IBS Mixed pattern, to submit their expression of interest within the next few days otherwise any opportunity for recruitment may have lapsed. It is simply a matter of going to the Anatara website or by using ibstrial.au to find the link to the clinic in their geographical zone to register an interest.”

At 13:00 AEDT, Anatara was trading at 5.5 cents – a fall of 3.51% since the market opened.

Join the discussion: See what HotCopper users are saying about Anatara and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.